Is the Combine Prolotherapy More Effective Than the Traditional Prolotherapy in Patients With Temporomandibular Joint Hypermobility?

NCT07020455 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2025-06-13

No results posted yet for this study

Summary

1. Diagnosis and Indication You have been diagnosed with temporomandibular joint (TMJ) hypermobility and/or dysfunction, characterized by symptoms such as jaw clicking, locking, pain in the joint area, or difficulty in opening and closing the mouth. After clinical and radiographic evaluation, the recommended treatment includes arthrocentesis and prolotherapy, either alone or in combination.
2. Description of Procedures

A. TMJ Arthrocentesis:

This is a minimally invasive procedure in which small needles are inserted into the TMJ space to irrigate the joint using sterile fluid (e.g., Ringer's solution). The procedure aims to eliminate inflammatory mediators, release joint adhesions, and improve mandibular mobility. It is generally performed under local anesthesia in an outpatient setting.

B. Prolotherapy:

Prolotherapy involves the injection of an irritant solution (typically dextrose combined with a local anesthetic) into the joint capsule, ligaments, or surrounding tissue. The goal is to stimulate the body's natural healing response, promoting collagen production and tissue regeneration to improve joint stability and function.

C. Combined Approach:

In certain cases, both treatments may be performed during the same session to maximize clinical benefit-arthrocentesis addresses inflammation and mobility, while prolotherapy enhances long-term stabilization.
3. Benefits and Expected Outcomes Reduction in TMJ pain and joint clicking

Improved jaw function and range of motion

Stabilization of the joint and reduced recurrence of dislocation or subluxation

Minimally invasive and generally well-tolerated
4. Possible Risks and Complications

Although these procedures are generally safe, potential risks may include but are not limited to:

Mild pain or swelling at the injection site

Temporary facial numbness or weakness (rare and usually self-resolving)

Dizziness or light-headedness

Joint stiffness or infection (very rare)

Allergic reaction to anesthetic or injected substances
5. Alternatives to the Proposed Procedure

You have the right to consider other treatment options, which may include:

Physical therapy or jaw exercises

Oral splints or bite guards

Medication (analgesics, muscle relaxants)

Surgical interventions (if conservative methods fail)
6. Patient Instructions and Post-Procedure Care Avoid wide mouth opening, yawning, or chewing hard foods for several days

Use only recommended medications (e.g., acetaminophen/paracetamol); avoid anti-inflammatory drugs unless advised otherwise

Apply cold compresses to reduce swelling if necessary

Attend all scheduled follow-up appointments

Notify your doctor immediately if you experience severe pain, prolonged numbness, fever, or signs of infection

Conditions

  • Temporomandibular Disorders (TMD)
  • Temporomandibular Pain
  • Hypermobility Syndrome (Disorder)
  • Hypermobility, Joint
  • Arthrocentesis
  • Prolotherapy

Interventions

DRUG

prolotherapy solution of 20% dextrose

Polotherapy, it involves injecting an irritant solution into weakened joints, ligaments, or tendons to stimulate collagen production and tissue repair at fibro-osseous junctions.

DRUG

Arthrocentesis with ringer solution

Integrating arthrocentesis with prolotherapy may enhance therapeutic outcomes by addressing both the mechanical and inflammatory aspects of TMJ hypermobility. This dual-modality technique presents a promising minimally invasive option for clinicians managing patients with joint instability.

Sponsors & Collaborators

  • Karadeniz Technical University

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
17 Years
Max Age
46 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-01
Primary Completion
2022-01-01
Completion
2025-01-01

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07020455 on ClinicalTrials.gov